IFNB1 and myeloid sarcoma: Despite the increasing number of drugs that recently became available for therapy of MS, owing the well-established long-term safety profile and some concerns with alternative treatments such as the occurrence of progressive multifocal leukoencephalopathy (4), IFN-β treatment still remains one of the first-choice options for mild-to-moderate forms of relapsing MS (5).